CLAIMS

1. A solid solution pharmaceutical composition comprising: a) one or more therapeutic compounds having an activity that normalizes lipid levels and comprising about 5% to 55% by weight of the pharmaceutical composition; b) one or more room temperature solid lipids comprising about 30% to about 75% by weight of the pharmaceutical composition; c) one or more room temperature liquid lipids comprising about 1% to about 20% by weight of the pharmaceutical composition, wherein the solid solution pharmaceutical composition has a melting point of 30°C or higher.

2. The solid solution pharmaceutical composition according to Claim 1, wherein the one or more therapeutic compound has is about 20% to about 30% by weight of the pharmaceutical composition.

3. The solid solution pharmaceutical composition according to Claim 1 or Claim 2, wherein the one or more room temperature solid lipid is about 35% to about 45% by weight of the pharmaceutical composition.

4. The solid solution pharmaceutical composition according to any one of Claims 1-3, wherein the one or more room temperature liquid lipid is about 1% to about 10% by weight of the pharmaceutical composition.

5. The solid solution pharmaceutical composition according to any one of Claims 1-4, wherein the one or more therapeutic compound is a NSAID, a PPARα agonist, a PPARβ/δ agonist, a PPARγ agonist, a Glitazar, a Ryanodine receptor antagonist, a nuclear receptor binding agent, an Angiotension II recetor antagonist, a ACE inhibitor, a phosphodiesterase inhibitor, a fibrate, a statin, a tocotrienol, a niacin, a bile acid sequestrants (resin), a cholesterol absorption inhibitor, a pancreatic lipase inhibitor, a sympathomimetic amine, a cancer drug, Metformin, Curcumin, glycyrrhetinic acid, 6-shogaol, an antibiotic, an anti-helmintic drug, or a an anti-malaria drug.

6. The solid solution pharmaceutical composition according to any one of Claims 1-5, wherein the one or more room temperature solid lipid have a melting point of about 40°C to about 50°C.

7. The solid solution pharmaceutical composition according to Claim 6, wherein the one or more room temperature solid lipids comprise one or more glycerolipids.

8. The solid solution pharmaceutical composition according to Claim 7, wherein the one or more glycerolipids comprise a triglyceride with one saturated or unsaturated fatty acid having a carbon length of C_{12}-C_{24}, two saturated or unsaturated fatty acids each having a carbon length of C_{12}-C_{24}, or three saturated or unsaturated fatty acids each having a carbon length of C_{12}-C_{24}.

9. The solid solution pharmaceutical composition according to Claims 8, wherein the one or more room temperature solid lipids comprises a mixture of saturated C_{10}-C_{18} triglycerides having a melting point range of about 41°C to 45°C.

10. The solid solution pharmaceutical composition according to any one of Claims 1-9, wherein the one or more room temperature liquid lipids comprises one or more partially hydrogenated fats.

11. The solid solution pharmaceutical composition according to any one of Claims 1-9, wherein the one or more room temperature liquid lipids comprises one or more monoglycerides,

12. The solid solution pharmaceutical composition according to Claims 8, wherein the one or more monoglycerides comprises glycerol monolinoleate.

13. The solid solution pharmaceutical composition according to any one of Claims 1-12, wherein the solid solution pharmaceutical composition further comprises one or more stabilizing agents and/or one or more neutralizing agents.

14. The solid solution pharmaceutical composition according to Claim 13, wherein the one or more stabilizing agents comprises about 1% to about 5% by weight of the pharmaceutical composition.

15. The solid solution pharmaceutical composition according to Claim 14, wherein the one or more stabilizing agents comprises a liquid glycol polymer, a monohydric alcohol, isosorbide dimethyl ether, and diethylene glycol monoethyl ether (2-(2-ethoxyethoxy)ethanol).

16. The solid solution pharmaceutical composition according to Claim 15, wherein the liquid glycol polymer is a liquid PEG polymer and/or a liquid PPG polymer.

17. The solid solution pharmaceutical composition according to Claim 15, wherein the monohydric alcohol is ethanol.

18. The solid solution pharmaceutical composition according to Claim 13, wherein the one or more neutralizing agents comprises about 5% to 55% by weight of the pharmaceutical composition.

18. The solid solution pharmaceutical composition according to Claim 18, wherein the one or more neutralizing agents comprises one or more fatty acids, sodium acetate, or triethanolamine.

19. The solid solution pharmaceutical composition according to Claim 18, wherein the one or more fatty acids comprises a C_{16}-C_{18} fatty acid

20. The solid solution pharmaceutical composition according to Claim 19, wherein the C_{16}-C_{18} fatty acid comprises stearic acid.

CLAIMS

1. A solid solution pharmaceutical composition comprising:

   a) one or more statins in an amount of about 1% to about 30% by weight of the pharmaceutical composition;

   b) one or more pharmaceutically-acceptable hard fats in an amount of about 30% to about 75% by weight of the pharmaceutical composition;

   c) one or more pharmaceutically-acceptable monoglycerides or acetylated monoglycerides that is liquid at room temperature in an amount of about 8% to about 40% by weight of the pharmaceutical composition,

   wherein the solid solution pharmaceutical composition is formulated to be a solid at a temperature of about 15°C or lower.

2. The solid solution pharmaceutical composition according to Claim 1, wherein the amount of the one or more statins is about 1% to about 15% by weight of the pharmaceutical composition.

3. The pharmaceutical composition according to Claim 1 or Claim 2, wherein the one or more statins comprises Atorvastatin, Fluvastatin, Lovastatin, Pitavastatin, Pravastatin, Rosuvastatin, and Simvastatin.

4. The solid solution pharmaceutical composition according to any one of Claims 1-3, wherein the amount of the one or more pharmaceutically-acceptable hard fats is at least 55% by weight of the pharmaceutical composition.

5. The solid solution pharmaceutical composition according to any one of Claims 1-4, wherein the one or more pharmaceutically-acceptable hard fats have a melting point of about 40°C to about 50°C.

6. The solid solution pharmaceutical composition according to Claim 5, wherein the one or more pharmaceutically-acceptable hard fats comprise one or more glycerolipids.

7. The solid solution pharmaceutical composition according to Claim 6, wherein the one or more glycerolipids comprise a triglyceride with one saturated or unsaturated fatty acid having a carbon length of C_{12}-C_{24}, two saturated or unsaturated fatty acids each having a carbon length of C_{12}-C_{24}, or three saturated or unsaturated fatty acids each having a carbon length of C_{12}-C_{24}.

8. The solid solution pharmaceutical composition according to Claim 6, wherein the one or more glycerolipids comprise a mixture of saturated C_{10}-C_{18} triglycerides having a melting point range of about 41°C to 45°C.

9. The solid solution pharmaceutical composition according to Claim 8, wherein the one or more glycerolipids comprise a mixture of saturated C_{10}-C_{18} triglycerides having a melting point range of about 43°C.

10. The solid solution pharmaceutical composition according to any one of Claims 1-9, wherein the amount of the one or more pharmaceutically-acceptable monoglycerides or acetylated monoglycerides is less than 35% by weight of the pharmaceutical composition.

11. The solid solution pharmaceutical composition according to any one of Claims 1-10, wherein the one or more pharmaceutically-acceptable monoglycerides or an acetylated monoglycerides comprise glycerol monomyristoleate, glycerol monopalmitoleate, glycerol monosapienate, glycerol monooleate, glycerol monoelaidate, glycerol monovaccenate, glycerol monolinoleate, glycerol monolinoelaidate, glycerol monolinolenate, glycerol monostearidonate, glycerol monoeicosenoate, glycerol monomeadate, glycerol monoarachidonate, glycerol monoeicosapentaenoate, glycerol monoerucate, glycerol monodocosahexaenoate, or glycerol mononervonate.

12. The solid solution pharmaceutical composition according to Claims 11, wherein the one or more pharmaceutically-acceptable monoglycerides or acetylated monoglycerides comprise glycerol monolinoleate.

13. Use of a pharmaceutical composition as defined in any one of Claims 1-12 in the manufacture of a medicament for the treatment of a cardiovascular disease.

14. The use according to Claim 13, wherein the cardiovascular disease is associated with a hyperlipidemia, a coronary heart disease, an atherosclerosis, a peripheral vascular disease, a vascular occlusive disease, a cardiomyopathy, a vasculitis, an inflammatory heart disease, an ischemic heart disease, a congestive heart failure, a hypertensive heart disease, a valvular heart disease, a hypertension, myocardial infarction, a diabetic cardiac conditions, an aneurysm; an embolism, a dissection, a pseudoaneurysm, a vascular malformation, a vascular nevus, a thrombosis, a varicose vein, or a stroke.